Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account
We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading
Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

Select Lymphoma Type ∨Select
Lymphoma
Type
Previously untreated Stage III/IV cHLPediatric previously untreated high-risk cHL

cHL post-auto-HSCT consolidation

Relapsed cHLR/R LBCL after ≥2 prior lines of systemic therapyPreviously untreated sALCL or other CD30-expressing PTCLRelapsed pcALCL or CD30-expressing MFRelapsed sALCL
Patient ManagementMOA and CD30 TestingResourcesPatient Assistance
Prescribing InformationPatient InformationIndicationsLoadingPatient Site
Identify Adverse Events Early
Identify adverse events early to help optimize patient outcomes1 Difficulty with activities of daily living may indicate peripheral neuropathy (PN)2,3Ask patients if they have any difficulty:
  • Monitor patients for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness1
  • Counsel patients to report any numbness or tingling in their hands or feet, or muscle weakness1
Address PN as early as possible with dose modificationsADCETRIS treatment causes a PN that is predominantly sensory1
  • Cases of peripheral motor neuropathy have also been reported1
  • ADCETRIS-induced PN is cumulative1
NCI peripheral neuropathy grading criteria (v6.0)*2
Grade 1 sensory PNMild symptoms
Grade 1 motor PNMild symptoms; clinical or diagnostic observations only
Grade 2 sensory and motor PNModerate symptoms; limiting instrumental ADL
Grade 3 sensory and motor PNSevere symptoms; limiting self-care ADL
Grade 4 sensory and motor PNLife-threatening consequences; urgent intervention indicated
Based on Common Terminology Criteria for Adverse Events (CTCAE v6.0).PN Incidence and Resolution RatesSelect Lymphoma Type Previously untreated adult Stage III/IV cHL
Peripheral neuropathy was identifiable, manageable, and resolved in most cases within 6 years1,4-8

The 3-, 4-, and 5-year data provided are not contained in the approved product labeling. Data are provided as supportive clinical information.

PN in patients treated with A+AVD in ECHELON-1 at 2 years1,5
  • 67% (442/662) experienced PN1
    • Grade 1 or 2: 56% (372/662)
    • ≥Grade 3: 11% (70/662)
  • Median time to onset (range)1
    • Any grade: 2 months (0-7)
    • Grade 2: 3 months (0-6)
    • Grade 3: 4 months (<1-7)
  • 7% (44/662) discontinued due to PN1,5
PN in patients treated with A+AVD in ECHELON-1 at 6 years1 
  • Median time to partial improvement (range)1
    • 2.9 months (<1-50)
  • Median time to complete improvement (range)1
    • <6.6 months (<1-67)
PN is recorded as last observation carried forward.Events were graded using the NCI CTCAE Version 4.03.
R/R LBCL after ≥2 prior lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapyRates of PN were similar across both study arms1,9

Dose modifications for PN in ADCETRIS-treated patients1:

  • Dose reduction due to PN: 6%
  • Permanent discontinuation due to PN: 4.5%
Resolution: Adverse event outcome is resolved with or without sequelae or has returned to baseline or lower severity with no subsequent increase in severity. Improved: Adverse event decreased by at least 1 severity grade from worst grade with no increase in severity grade after that.9Peripheral neuropathy events were identified using the broad Standardized MedDRA Query (SMQ) and graded by severity per NCI CTCAE version 5.0.10,11Includes peripheral sensory neuropathy, peripheral motor neuropathy, paresthesia, hypoesthesia, neuropathy peripheral, hypoesthesia oral, oral dysesthesia, neuralgia, paresthesia oral.1
Previously untreated sALCL or other CD30-expressing PTCLsMost PN with A+CHP completely resolved or improved by 5 years1,12,13

The follow-up analysis of PN at 5 years was not prespecified in the protocol, is descriptive in nature, and offers supportive, but not conclusive, clinical information only. This analysis was not statistically powered to determine differences between treatment arms.

Similar incidence of new or worsening PN was observed between treatment arms

  • During the study, 55% (124/226) of patients in the CHOP arm reported PN12
  • At 5 years, 19% (42/226) of patients in the CHOP arm had residual PN12
  • During the study, 52% (117/223) of patients in the A+CHP arm reported PN (34% Grade 1, 15% Grade 2, 3% Grade 3, <1% Grade 4)1
  • Adverse reactions led to dose delays of ADCETRIS in 25% of patients, dose reduction in 9% (most often for PN), and discontinuation with or without the other CHP components in 7% (most often from PN and infection)1
A+CHP = ADCETRIS + cyclophosphamide, doxorubicin, and prednisone.
Dose ModificationsAct quickly with dose modifications for adverse eventsSelect Lymphoma Type Previously untreated Stage III/IV cHLPreviously untreated adult Stage III/IV cHL dosage and dose modificationsRecommended ADCETRIS dosage and administration:

Administer 1.2 mg/kg up to 120 mg§ in combination with AVD every 2 weeks until a maximum of 12 doses, disease progression, or unacceptable toxicity.1

  • Administer G-CSF primary prophylaxis beginning with Cycle 11
  • Do not mix ADCETRIS with, or administer as an infusion with, other medicinal products1
Dose modifications

Renal impairment dose modifications1

Degree Dose modifications
Mild  
(CrCL >50-80 mL/min)
1.2 mg/kg up to 120 mgII
every 2 weeks
Moderate  
(CrCL 30-50 mL/min)
Severe  
(CrCL <30 mL/min)
Avoid use

Hepatic impairment dose modifications1

Degree Dose modifications
Mild  
(Child-Pugh A)
0.9 mg/kg up to 90 mgII every 2 weeks
Moderate  
(Child-Pugh B)
Avoid use
Severe  
(Child-Pugh C)

PN dose modifications for adult patients1

Severity Dose modifications for PN
Grade 2
  • Reduce dose to 0.9 mg/kg up to a maximum of 90 mg§ every 2 weeks
Grade 3
  • Hold ADCETRIS dosing until improvement to Grade 2 or lower 
  • Restart at 0.9 mg/kg up to a maximum of 90 mgII every 2 weeks
  • Consider modifying dose of other neurotoxic chemotherapy agents
Grade 4
  • Discontinue dosing
Patients who develop PN may be able to receive a full course of treatment with dose modifications1
Example Text

Neutropenia dose modifications for adult patients1

SeverityDose modifications
Grade 3 or 4Administer G-CSF prophylaxis for subsequent cycles for patients not receiving G-CSF primary prophylaxis
The dose for patients weighing >100 kg should be calculated based on a weight of 100 kg.1NCI CTCAE Version 4.03 was used in the ECHELON-1 trial, and Version 6.0, current at time of publication (January 2026), is shown here for reference2:
  • Grade 1 sensory PN: Mild symptoms
  • Grade 1 motor PN: Mild symptoms; clinical or diagnostic observations only
  • Grade 2 sensory and motor PN: Moderate symptoms; limiting instrumental ADL
  • Grade 3 sensory and motor PN: Severe symptoms; limiting self-care ADL
  • Grade 4 sensory and motor PN: Life-threatening consequences; urgent intervention indicated
CrCL = creatinine clearance; G-CSF = granulocyte colony–stimulating factor.
Pediatric previously untreated high-risk cHLPreviously untreated pediatric high-risk cHL dosage and dose modificationsRecommended ADCETRIS dosage and administration:

Administer 1.8 mg/kg up to a maximum of 180 mg# in combination with chemotherapy every 3 weeks until a maximum of 5 doses.1

  • Administer G-CSF primary prophylaxis beginning with Cycle 11
  • Do not mix ADCETRIS with, or administer as an infusion with, other medicinal products1
Dose modifications

Renal impairment dose modifications1

Degree Dose modifications
Mild  
(CrCL >50-80 mL/min)
1.8 mg/kg up to a maximum of 180 mg#
every 3 weeks
Moderate  
(CrCL 30-50 mL/min)
Severe  
(CrCL <30 mL/min)
Avoid use

Hepatic impairment dose modifications1

Degree Dose modifications
Mild  
(Child-Pugh A)
1.2 mg/kg up to a maximum of 120 mg#
every 3 weeks
Moderate  
(Child-Pugh B)
Avoid use
Severe  
(Child-Pugh C)

PN dose modifications for pediatric patients1

Severity** Dose modifications for PN
Grade 2
  • Reduce dose of vincristine per prescribing information
  • Continue dosing with ADCETRIS
  • Resume vincristine at full dose if neuropathy improves to Grade ≤1 by day 8 of next cycle
Grade 3
  • Discontinue vincristine 
  • First occurrence: Hold ADCETRIS dosing until improvement to ≤Grade 2 then restart at 1.2 mg/kg up to a maximum of 120 mg
  • Second occurrence: Hold until improvement to ≤Grade 2 then restart at 0.8 mg/kg up to a maximum of 80 mg
  • Third occurrence: Discontinue ADCETRIS
Grade 4
  • Discontinue ADCETRIS and vincristine
Patients who develop PN may be able to receive a full course of treatment with dose modifications1
Example Text

Neutropenia dose modifications for pediatric patients1

SeverityDose modifications
Grade 3 or 4
  • Reduce dose to 1.2 mg/kg up to a maximum of 120 mg every 3 weeks in patients who are unable to start a cycle >5 weeks after the start of the previous cycle (>2-week delay) due to neutropenia
The dose for patients weighing >100 kg should be calculated based on a weight of 100 kg.1Peripheral neuropathy was assessed using the Balis Scale.1CrCL = creatinine clearance; G-CSF = granulocyte colony–stimulating factor.
cHL post–auto-HSCT consolidationcHL post–auto-HSCT consolidation dosage and dose modificationsRecommended ADCETRIS dosage and administration:

Administer 1.8 mg/kg up to a maximum of 180 mg†† every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity.1

  • Initiate ADCETRIS treatment within 4 to 6 weeks post-auto-HSCT or upon recovery from auto-HSCT.1
  • Do not mix ADCETRIS with, or administer as an infusion with, other medicinal products1
Dose modifications

Renal impairment dose modifications1

Degree Dose modifications
Mild  
(CrCL >50-80 mL/min)
1.8 mg/kg up to a maximum of 180 mg††
every 3 weeks
Moderate  
(CrCL 30-50 mL/min)
Severe  
(CrCL <30 mL/min)
Avoid use

Hepatic impairment dose modifications1

Degree Dose modifications
Mild  
(Child-Pugh A)
1.2 mg/kg up to a maximum of 120 mg††
every 3 weeks
Moderate  
(Child-Pugh B)
Avoid use
Severe  
(Child-Pugh C)

PN dose modifications for adult patients1

SeverityDose modifications for PN
Grade 2
  • New or worsening Grade 2 or 3: Hold dosing until improvement to baseline or Grade 1 
  • Restart at 1.2 mg/kg up to a maximum of 120 mg†† every 3 weeks
Grade 3
Grade 4
  • Discontinue dosing
Patients who develop PN may be able to receive a full course of treatment with dose modifications1
Example Text

Neutropenia dose modifications for adult patients1

SeverityDose modifications
Grade 3 or 4
  • Hold dosing until improvement to baseline or Grade 2 or lower. Consider G-CSF prophylaxis for subsequent cycles
  • Recurrent Grade 4 despite G-CSF prophylaxis: Consider discontinuation or dose reduction to 1.2 mg/kg up to a maximum of 120 mg every 3 weeks
The dose for patients weighing >100 kg should be calculated based on a weight of 100 kg.1CrCL = creatinine clearance; G-CSF = granulocyte colony–stimulating factor.
Relapsed cHLRelapsed cHL dosage and dose modificationsRecommended ADCETRIS dosage and administration:

Administer 1.8 mg/kg up to a maximum of 180 mg‡‡ every 3 weeks until disease progression or unacceptable toxicity.1

  • Do not mix ADCETRIS with, or administer as an infusion with, other medicinal products1
Dose modifications

Renal impairment dose modifications1

Degree Dose modifications
Mild  
(CrCL >50-80 mL/min)
1.8 mg/kg up to a maximum of 180 mg‡‡
every 3 weeks
Moderate  
(CrCL 30-50 mL/min)
Severe  
(CrCL <30 mL/min)
Avoid use

Hepatic impairment dose modifications1

DegreeDose modifications
Mild  
(Child-Pugh A)
1.2 mg/kg up to a maximum of 120 mg††
every 3 weeks
Moderate  
(Child-Pugh B)
Avoid use
Severe  
(Child-Pugh C)

PN dose modifications for adult patients1

SeverityDose modifications for PN
Grade 2
  • New or worsening Grade 2 or 3: Hold dosing until improvement to baseline or Grade 1 
  • Restart at 1.2 mg/kg up to a maximum of 120 mg†† every 3 weeks 
Grade 3
Grade 4
  • Discontinue dosing
Patients who develop PN may be able to receive a full course of treatment with dose modifications1
Example Text

Neutropenia dose modifications for adult patients1

SeverityDose modifications
Grade 3 or 4
  • Hold dosing until improvement to baseline or Grade 2 or lower. Consider G-CSF prophylaxis for subsequent cycles
  • Recurrent Grade 4 despite G-CSF prophylaxis: Consider discontinuation or dose reduction to 1.2 mg/kg up to a maximum of 120 mg every 3 weeks
The dose for patients weighing >100 kg should be calculated based on a weight of 100 kg.1CrCL = creatinine clearance; G-CSF = granulocyte colony–stimulating factor.
R/R LBCL after ≥2 prior lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapyR/R LBCL after ≥2 prior lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy dosage and dose modificationsRecommended ADCETRIS dosage and administration:Administer 1.2 mg/kg up to a maximum of 120 mg§§ in combination with lenalidomide and rituximab every 3 weeks until disease progression or unacceptable toxicityIIII1
  • Administer G-CSF primary prophylaxis beginning with Cycle 11
Dose Adjustments

Recommended dosage in patients with renal impairment1

  • No dosage adjustment is required for mild renal impairment (CrCL greater than 50-80 mL/min) and moderate renal impairment (CrCL 30-50 mL/min)
  • Avoid use in patients with severe renal impairment (CrCL less than 30 mL/min)

Recommended dosage in patients with hepatic impairment1

  • Reduce the dosage of ADCETRIS to 0.9 mg/kg up to a maximum of 90 mg every 3 weeks for patients with mild hepatic impairment (total bilirubin ≤ upper limit of normal [ULN] and aspartate transaminase [AST] > ULN, or total bilirubin >1 to 1.5 × ULN and any AST)
  • Avoid use in patients with moderate and severe hepatic impairment (total bilirubin >1.5 × ULN)
  • Hepatic impairment is defined per the National Cancer Institute Organ Dysfunction Working Group
The dose for patients weighing greater than 100 kg should be calculated based on a weight of 100 kg.1Starting with cycle 2, rituximab intravenous treatment could be substituted with rituximab and hyaluronidase human via subcutaneous injection every 3 weeks.1Dose modifications

Dose modifications for PN and neutropenia1

Scroll left to view table
Recommended dosage Severity¶¶ Dose modifications
Peripheral neuropathy
1.2 mg/kg up to a maximum of 120 mg every 3 weeks Grade 2
  • Sensory neuropathy: If resolves to Grade 1 or lower before the next scheduled dose, resume at the same dose level. If Grade 2 persists at the next scheduled dose, reduce one dose level 
  • Motor neuropathy: Reduce dosage to 0.9 mg/kg up to a maximum of 90 mg every 3 weeks
Grade 3
  • Sensory neuropathy: Hold ADCETRIS dosing until improvement to Grade 2 or lower, then restart treatment at a reduced dosage of 0.9 mg/kg up to a maximum of 90 mg every 3 weeks 
  • Motor neuropathy: Discontinue dosing
Grade 4
  • Discontinue dosing
Neutropenia
1.2 mg/kg up to a maximum of 120 mg every 3 weeks Grade 3 or 4
  • Hold dosing until improvement to baseline or Grade 2 or lower 
  • Reduce/discontinue lenalidomide dose per prescribing information
  • Administer G-CSF prophylaxis for subsequent cycles for patients not receiving primary G-CSF prophylaxis
Patients who develop PN may be able to receive a full course of treatment with dose modifications1
Example Text
Based on Common Terminology Criteria for Adverse Events (CTCAE v5.0).
Previously untreated sALCL or other CD30-expressing PTCLsPreviously untreated sALCL or other CD30-expressing PTCLs dosage and dose modificationsRecommended ADCETRIS dosage and administration:

Administer 1.8 mg/kg up to a maximum of 180 mg## every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity.

  • Do not mix ADCETRIS with, or administer as an infusion with, other medicinal products1
Dose modifications

Renal impairment dose modifications1

Degree Dose modifications
Mild  
(CrCL >50-80 mL/min)
1.8 mg/kg up to a maximum of 180 mg##
every 3 weeks
Moderate  
(CrCL 30-50 mL/min)
Severe  
(CrCL <30 mL/min)
Avoid use

Hepatic impairment dose modifications1

Degree Dose modifications
Mild  
(Child-Pugh A)
1.2 mg/kg up to a maximum of 120 mg## every 3 weeks
Moderate  
(Child-Pugh B)
Avoid use
Severe  
(Child-Pugh C)

PN dose modifications for adult patients1

SeverityDose modifications for PN
Grade 2
  • Sensory neuropathy: Continue treatment at same dose
  • Motor neuropathy: Reduce dose to 1.2 mg/kg up to a maximum of 120 mg## every 3 weeks
Grade 3
  • Sensory neuropathy: Reduce dose to 1.2 mg/kg, up to a maximum of 120 mg## every 3 weeks
  • Motor neuropathy: Discontinue dosing
Grade 4
  • Discontinue dosing
Patients who develop PN may be able to receive a full course of treatment with dose modifications1
Example Text

Neutropenia dose modifications for adult patients1

SeverityDose modifications
Grade 3 or 4Administer G-CSF prophylaxis in subsequent cycles for patients not receiving primary G-CSF
The dose for patients weighing >100 kg should be calculated based on a weight of 100 kg.1CrCL = creatinine clearance; G-CSF = granulocyte colony–stimulating factor.
Relapsed pcALCL or CD30-expressing MFRelapsed pcALCL or CD30-expressing MF dosage and dose modificationsRecommended ADCETRIS dosage and administration:

Administer 1.8 mg/kg up to a maximum of 180 mg*** every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity.1

  • Do not mix ADCETRIS with, or administer as an infusion with, other medicinal products1
Dose modifications

Renal impairment dose modifications1

Degree Dose modifications
Mild  
(CrCL >50-80 mL/min)
1.8 mg/kg up to a maximum of 180 mg***
every 3 weeks
Moderate  
(CrCL 30-50 mL/min)
Severe  
(CrCL <30 mL/min)
Avoid use

Hepatic impairment dose modifications1

Degree Dose modifications
Mild  
(Child-Pugh A)
1.2 mg/kg up to a maximum of 120 mg***
every 3 weeks
Moderate  
(Child-Pugh B)
Avoid use
Severe  
(Child-Pugh C)

PN dose modifications for adult patients1

SeverityDose modifications for PN
Grade 2
  • New or worsening Grade 2 or 3: Hold dosing until improvement to baseline or Grade 1 
  • Restart at 1.2 mg/kg up to a maximum of 120 mg*** every 3 weeks 
Grade 3
Grade 4
  • Discontinue dosing
Patients who develop PN may be able to receive a full course of treatment with dose modifications1
Example Text

Neutropenia dose modifications for adult patients1

SeverityDose modifications
Grade 3 or 4
  • Hold dosing until improvement to baseline or Grade 2 or lower. Consider G-CSF prophylaxis for subsequent cycles
  • Recurrent Grade 4 despite G-CSF prophylaxis: Consider discontinuation or dose reduction to 1.2 mg/kg up to a maximum of 120 mg every 3 weeks
The dose for patients weighing >100 kg should be calculated based on a weight of 100 kg.1CrCL = creatinine clearance; G-CSF = granulocyte colony–stimulating factor.
Relapsed sALCLRelapsed sALCL dosage and dose modificationsRecommended ADCETRIS dosage and administration:

Administer 1.8 mg/kg up to a maximum of 180 mg††† every 3 weeks until disease progression or unacceptable toxicity.1

  • Do not mix ADCETRIS with, or administer as an infusion with, other medicinal products1
Dose modifications

Renal impairment dose modifications1

Degree Dose modifications
Mild  
(CrCL >50-80 mL/min)
1.8 mg/kg up to a maximum of 180 mg†††
every 3 weeks
Moderate  
(CrCL 30-50 mL/min)
Severe  
(CrCL <30 mL/min)
Avoid use

Hepatic impairment dose modifications1

Degree Dose modifications
Mild  
(Child-Pugh A)
1.2 mg/kg up to a maximum of 120 mg††† every 3 weeks
Moderate  
(Child-Pugh B)
Avoid use
Severe  
(Child-Pugh C)

PN dose modifications for adult patients1

SeverityDose modifications for PN
Grade 2
  • New or worsening Grade 2 or 3: Hold dosing until improvement to baseline or Grade 1 
  • Restart at 1.2 mg/kg up to a maximum of 120 mg††† every 3 weeks 
Grade 3
Grade 4
  • Discontinue dosing
Patients who develop PN may be able to receive a full course of treatment with dose modifications1
Example Text

Neutropenia dose modifications for adult patients1

SeverityDose modifications
Grade 3 or 4
  • Hold dosing until improvement to baseline or Grade 2 or lower. Consider G-CSF prophylaxis for subsequent cycles
  • Recurrent Grade 4 despite G-CSF prophylaxis: Consider discontinuation or dose reduction to 1.2 mg/kg up to a maximum of 120 mg every 3 weeks
The dose for patients weighing >100 kg should be calculated based on a weight of 100 kg.1CrCL = creatinine clearance; G-CSF = granulocyte colony–stimulating factor.
Patient EducationTalking to patients about what to expect from treatment with ADCETRIS

Clear communication with patients is key in helping to detect and respond to adverse events early. Use the PN management guide with your patients taking ADCETRIS to help ensure they know when to reach out with concerns.

See how ADCETRIS works Go to ADCETRIS MOA Loading Resources for your patients and practice Find Useful Resources LoadingADL = activities of daily living; AE = adverse events; CAR T = chimeric antigen receptor T-cell, cHL = classical Hodgkin lymphoma; HSCT = hematopoietic stem cell transplantation; PN = peripheral neuropathy; R/R LBCL = relapsed or refractory large B-cell lymphoma; MF = mycosis fungoides; MOA = mechanism of action; NCI = National Cancer Institute; pcALCL = primary cutaneous anaplastic large cell lymphoma; PTCL = peripheral T-cell lymphoma; sALCL = systemic anaplastic large cell lymphoma.References:ADCETRIS Prescribing Information. Bothell, WA: Seagen Inc.National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). v6.0. Accessed January 31, 2026. https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events/ctcae-v6.pdfZajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019;20:1451.Ansell SM, Radford J, Connors JM, et al. Overall survival with brentuximab vedotin in Stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2022;387:310-320.Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378:331-344.Straus DJ, Długosz-Danecka M, Connors JM, et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021;8:e410-e421.Bartlett NL, Straus DJ, Długosz-Danecka M, et al. Brentuximab vedotin with chemotherapy for Stage III/IV classical Hodgkin lymphoma (cHL): 4-year update of the ECHELON-1 Study. Poster presented at: 61st Annual Meeting of the American Society of Hematology; December 7-10, 2019; Orlando, FL.Straus DJ, Długosz-Danecka M, Alekseev S, et al. Brentuximab vedotin with chemotherapy for stage III/ IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood. 2020;135:735-742.Data on file. Seagen Inc.Bartlett NL, Hahn U, Kim WS, et al. Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma. J Clin Oncol. 2025;43(9):1061-1072.Bartlett NL, Hahn U, Kim WS, et al. Supplement to: Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma. J Clin Oncol. 2025;43(9):1061-1072.Horwitz S, O'Connor OA, Pro B, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33:288-298.Horwitz S, O’Connor OA, Pro B, et al. The ECHELON-2 trial: 5-year results of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma. Virtual presentation at: 62nd Annual Meeting of the American Society of Hematology; December 5-8, 2020.
Available on this page:

Share this patient guide with your patients who are interested in learning more about PN symptoms

Download Guide  Loading

Learn more about Dosing and Administration for ADCETRIS

Download Guide  Loading

To report an adverse event, please call 1‑800‑438‑1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-A1T-USA-1084
You are now leaving PfizerProYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
PP-MCL-USA-0367
Indications

ADCETRIS® (brentuximab vedotin) is indicated for the treatment of:

Previously untreated Stage III/IV cHL

  • Adult patients with previously untreated Stage III/IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.

Previously untreated high risk cHL

  • Pediatric patients 2 years and older with previously untreated high risk cHL, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.

cHL post-auto-HSCT consolidation

  • Adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.

Relapsed cHL

  • Adult patients with cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.

Previously untreated sALCL or other CD30-expressing PTCL

  • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.

Relapsed sALCL

  • Adult patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen.

Relapsed pcALCL or CD30-expressing MF

  • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.

Relapsed and Refractory Large B-Cell Lymphoma (LBCL)

  • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto‑HSCT or chimeric antigen receptor (CAR) T-cell therapy, in combination with lenalidomide and a rituximab product.

Please see full Prescribing Information, including BOXED WARNING, for ADCETRIS.

Important Safety Information

BOXED WARNING

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): JC virus infection resulting in PML and death can occur in ADCETRIS-treated patients.

CONTRAINDICATION

Contraindicated with concomitant bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation).

WARNINGS AND PRECAUTIONS
Peripheral neuropathy (PN):
ADCETRIS causes PN that is predominantly sensory. Cases of motor PN have also been reported. ADCETRIS-induced PN is cumulative. Monitor for symptoms such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness. Patients experiencing new or worsening PN may require a delay, change in dose, or discontinuation of ADCETRIS.

Anaphylaxis and infusion reactions: Infusion-related reactions (IRR), including anaphylaxis, have occurred with ADCETRIS. Monitor patients during infusion. If an IRR occurs, interrupt the infusion and institute appropriate medical management. If anaphylaxis occurs, immediately and permanently discontinue the infusion and administer appropriate medical therapy. Premedicate patients with a prior IRR before subsequent infusions. Premedication may include acetaminophen, an antihistamine, and a corticosteroid.

Hematologic toxicities: Fatal and serious cases of febrile neutropenia have been reported with ADCETRIS. Prolonged (≥1  week) severe neutropenia and Grade 3 or 4 thrombocytopenia or anemia can occur with ADCETRIS.

Administer G-CSF primary prophylaxis beginning with Cycle 1 for adult  patients who receive ADCETRIS in combination with chemotherapy for previously untreated Stage III/IV cHL or previously untreated PTCL or relapsed or refractory LBCL and pediatric patients who receive ADCETRIS in combination with chemotherapy for previously untreated high risk cHL.

Monitor complete blood counts prior to each ADCETRIS dose. Monitor more frequently for patients with Grade 3 or 4 neutropenia. Monitor patients for fever. If Grade 3 or 4 neutropenia develops, consider dose delays,  reductions, discontinuation, or G-CSF prophylaxis with subsequent doses.

Serious infections and opportunistic infections: Infections such as pneumonia, bacteremia, and sepsis or septic shock (including  fatal outcomes) have been reported in ADCETRIS-treated patients. Closely monitor patients during treatment for infections.

Tumor lysis syndrome: Patients with rapidly proliferating tumor and high tumor burden may be at increased risk. Monitor closely and take appropriate measures.

Increased toxicity in the presence of severe renal impairment: The frequency of ≥Grade 3 adverse reactions and deaths was greater in patients with severe renal impairment. Avoid use in patients with severe renal impairment.

Increased toxicity in the presence of moderate or severe hepatic impairment: The frequency of ≥Grade 3 adverse reactions and deaths was greater in patients with moderate or severe hepatic impairment. Avoid use in patients with moderate or severe hepatic impairment.

Hepatotoxicity: Fatal and serious cases have occurred in ADCETRIS-treated patients. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and occurred after the first ADCETRIS dose or rechallenge. Preexisting liver disease, elevated baseline liver enzymes, and concomitant medications may increase the risk. Monitor liver enzymes and bilirubin. Patients with new, worsening, or recurrent hepatotoxicity may require a delay, change in dose, or discontinuation of ADCETRIS.

PML: Fatal cases of JC virus infection resulting in PML have been reported in ADCETRIS-treated patients. First onset of symptoms occurred at various times from initiation of ADCETRIS, with some cases occurring within 3 months of initial exposure. In addition to ADCETRIS therapy, other possible contributory factors include prior therapies and underlying disease that may cause immunosuppression. Consider PML diagnosis in patients with new-onset signs and symptoms of central nervous system abnormalities. Hold ADCETRIS if PML is suspected and discontinue ADCETRIS if PML is confirmed.

Pulmonary toxicity: Fatal and serious events of noninfectious pulmonary toxicity, including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome, have been reported. Monitor patients for signs and symptoms, including cough and  dyspnea. In the event of new or worsening pulmonary symptoms, hold ADCETRIS dosing during evaluation and until symptomatic improvement.

Serious dermatologic reactions: Fatal and serious cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with ADCETRIS. If SJS or TEN occurs, discontinue ADCETRIS and administer appropriate medical therapy.

Gastrointestinal (GI) complications: Fatal and serious cases of acute pancreatitis have been reported. Other fatal and serious GI complications include perforation, hemorrhage, erosion, ulcer, intestinal obstruction, enterocolitis, neutropenic colitis, and ileus. Lymphoma with preexisting GI involvement may increase the risk of perforation. In the event of new or worsening GI symptoms, including severe abdominal pain, perform a prompt diagnostic evaluation and treat appropriately.

Hyperglycemia: Serious cases, such as new-onset hyperglycemia, exacerbation of preexisting diabetes mellitus, and ketoacidosis (including fatal outcomes) have been reported with ADCETRIS. Hyperglycemia occurred more frequently in patients with high body mass index or diabetes. Monitor serum glucose and if hyperglycemia develops, administer anti-hyperglycemic medications as clinically indicated.

Embryo-fetal toxicity: Based on the mechanism of action and animal studies, ADCETRIS can cause fetal harm. Advise females of reproductive potential of this potential risk, and to use effective contraception during ADCETRIS treatment and for 2 months after the last dose of ADCETRIS. Advise male patients with female partners of reproductive potential to use effective contraception during ADCETRIS  treatment and for 4 months after the last dose of ADCETRIS.

ADVERSE REACTIONS
The most common adverse reactions (≥20%) in adult patients are  peripheral neuropathy, nausea, fatigue, musculoskeletal pain, constipation, diarrhea, vomiting, pyrexia, upper respiratory tract infection, mucositis, abdominal pain, and rash. The most common laboratory abnormalities (≥20%) in adult patients are decreased  neutrophils, increased creatinine, decreased hemoglobin, decreased lymphocytes, increased glucose, increased ALT, and increased AST. 

The most common Grade ≥3 adverse reactions (≥5%) in combination with AVEPC in pediatric patients were neutropenia, anemia, thrombocytopenia, febrile neutropenia, stomatitis, and infection.

DRUG INTERACTIONS
Concomitant use of strong CYP3A4 inhibitors has the potential to affect  the exposure to monomethyl auristatin E (MMAE). Closely monitor adverse reactions.

USE IN SPECIAL POPULATIONS
Lactation: Breastfeeding is not recommended during ADCETRIS treatment.

Please see full Prescribing Information, including BOXED WARNING, for ADCETRIS.IndicationsADCETRIS® (brentuximab vedotin) is indicated for the treatment of:

Previously untreated Stage III/IV cHL
  • Adult patients with previously untreated Stage III/IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.
Previously untreated high risk cHL
  • Pediatric patients 2 years and older with previously untreated high risk cHL, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.
cHL post-auto-HSCT consolidation
  • Adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.
Relapsed cHL
  • Adult patients with cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.
Previously untreated sALCL or other CD30-expressing PTCL
  • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.
Relapsed sALCL
  • Adult patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen.
Relapsed pcALCL or CD30-expressing MF
  • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.
Relapsed and Refractory Large B-Cell Lymphoma (LBCL)
  • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto‑HSCT or chimeric antigen receptor (CAR) T-cell therapy, in combination with lenalidomide and a rituximab product.